Liquid Biopsy : A Narrative Review
Keywords:
Liquid biopsy, Oncology, Application, Diagnostic tool, Limitations
Abstract
Liquid biopsy has emerged as an important diagnostic method in the oncology discipline. Investigation of CTCs( circulating tumor cells), microRNAs, extracellular vesicles, and ctDNA(circulating tumor DNA, liquid biopsies allows understanding of the treatment feedback, tumor heterogeneity, individualized cancer treatment, and lowest residual disease recognition. Liquid biopsies show various advantages more favorable, less invasive, and more explanatory for directing personalized treatment recommendations. Liquid biopsies are being employed in clinical oncology, especially for those patients suffering from metastatic diseases.In this present review, the components and clinical applications of liquid biopsies are discussed so that we can understand about basics of liquid biopsy. In this review, literature or information on liquid biopsy is discussed. English language articles were scrutinize in plentiful directory or databases like Pubmed, Scopus, Web of Science, Science direct, Google scholar
References
1. Ginkel J H V, Huibers M M H, Noorlag R, Bree R, Van R J J, Willems S M. Liquid Biopsy: A Future Tool for Posttreatment Surveillance in Head and Neck Cancer? Pathobiology 2017; 84:115–120
2. Aro K, Wei F, Wong D T, Tu M. Saliva Liquid Biopsy for Point-of- Care Applications. Front Public Health 2017; 5:77
3. D. Chen, T. Xu, S. Wang, H. Chang, T. Yu, Y. Zhu, J. Chen, Liquid Biopsy Applications in the Clinic, Mol Diagn Ther 24 (2020) 125–132
4. M. Nikanjam, S. Kato, R. Kurzrock, Liquid biopsy: current technology and clinical applications, J Hematol Oncol 15 (2022) 131
5. M.J. Ijzerman, J. de Boer, A. Azad, K. Degeling, J. Geoghegan, C. Hewitt, F. Hollande, B. Lee, Y.H. To, R.W. Tothill, G. Wright, J. Tie, S.-J. Dawson, Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late, Diagnostics (2021),
6. T. Ashworth, Med. J. Aust., 1869, 14, 146.
7. I. J. Fidler, Eur. J. Cancer, 1973, 9, 223–227.
8. D. R. Coman, R. P. deLong and M. McCutcheon, Cancer Res., 1951, 11, 648.
9. I. Zeidman, Cancer Res., 1957, 17, 157–162.
10. Z. Deng, S. Wu, Y. Wang, D. Shi, Circulating tumour cell isolation for cancer diagnosis and prognosis, eBioMedicine 83 (2022),
11. P. Pinzani, V. D’Argenio, M. Del Re, C. Pellegrini, F. Cucchiara, F. Salvianti, S. Galbiati, Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumours, 59 (2021) 1181-1200.
12. B. Trujillo, A. Wu, D. Wetterskog, G. Attard, Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges, British Journal of Cancer 127 (2022) 1394–1402
13. H. Zhang, X. Lin, Y. Huang, M. Wang, C. Cen, S. Tang, M.R. Dique, L. Cai, M. A. Luis, J. Smollar, Y. Wan, F. Cai, Detection Methods and Clinical Applications of Circulating Tumour Cells in Breast Cancer, Frontiers in Oncology 11 2021
14. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90.
15. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyurek LM, Lindahl P, Nilsson J. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med. 2015;7:308re308-308re308
16. E.S. Lianidou, A. Strati, A. Markou, Circulating tumour cells as promising novel biomarkers in solid cancers, Critical Reviews in Clinical Laboratory Sciences 51 (2014) 160–171
17. E. Heitzer, P. Ulz, J.B. Geigl, Circulating Tumour DNA as a Liquid Biopsy for Cancer, Clinical Chemistry 61 (2015) 112–123,
18. Q. Chen, Z.-H. Zhang, S. Wang, J.-H. Lang, Circulating cell-free DNA or circulating tumour DNA in the management of ovarian and endometrial cancer, OncoTargets and therapy 12 (2019) 11517
19. M. Ignatiadis, G.W. Sledge, S.S. Jeffrey, Liquid biopsy enters the clinic — implementation issues and future challenges, Nature Reviews Clinical Oncology 18 (2021) 297–312.
20. A.J. Bronkhorst, V. Ungerer, S. Holdenrieder, The emerging role of cell-free DNA as a molecular marker for cancer management, Biomolecular Detection and Quantification 17 (2019),
21. B. Bondhopadhyay, S. Sisodiya, F.A. Alzahrani, M.A. Bakhrebah, A. Chikara, V. Kasherwal, A. Khan, J. Rani, S.A. Dar, N. Akhter, P. Tanwar, U. Agrawal, S. Hussain, Exosomes: A Forthcoming Era of Breast Cancer Therapeutics, Cancers (2021)
22. C.A. Fitts, N. Ji, Y. Li, C. Tan, Exploiting exosomes in cancer liquid biopsies and drug delivery, Advanced healthcare materials 8 (2019), 1801268,
23. R. Kalluri, The biology and function of exosomes in cancer, The Journal of clinical investigation 126 (2016) 1208–1215, h
24. Oxnard GR, Thress KS, Alden RS, et al.: Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016, 34:3375-82.
25. Alix-Panabières C, Pantel K: Challenges in circulating tumour cell research . Nat Rev Cancer. 2014, 14:623-31.
26. Abbosh C, Birkbak NJ, Wilson GA, et al.: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017, 545:446-51.
27. Misawa K, Yamada S, Mima M, Nakagawa T, Kurokawa T, Imai A, et al.Long interspersed nuclear element 1 hypomethylation has novel prognostic value and potential utility in liquid biopsy for oral cavity cancer. Biomarker Research 2020; 8:53
28. Ginkel J H V, Huibers M M H, Noorlag R, Bree R, Van R J J, Willems S M. Liquid Biopsy: A Future Tool for Posttreatment Surveillance in Head and Neck Cancer? Pathobiology 2017; 84:115–120
29. Cui Y, Kim HS, Cho ES, Han D, Park J A, Park JY, Nam W, Kim HJ, Cha IH, Cha YH. Longitudinal detection of somatic mutations in saliva and plasma for the surveillance of oral squamous cell carcinomas. PLoS ONE 202; 16(9): e0256979
30. Khan RS, Khurshid Z, Yahya Ibrahim Asiri F. Advancing Point-of-Care (PoC) Testing Using Human Saliva as Liquid Biopsy. Diagnostics (Basel). 2017;7(3):39.
31. Michela B. Liquid Biopsy: A Family of Possible Diagnostic Tools. Diagnostics (Basel). 2021;11(8):1391.
32. J.J. Underwood, R.S. Quadri, S.P. Kalva, H. Shah, A.R. Sanjeevaiah, M.S. Beg, P. D. Sutphin, Liquid Biopsy for Cancer: Review and Implications for the Radiologist, Radiology 294 (2019) 5–17
2. Aro K, Wei F, Wong D T, Tu M. Saliva Liquid Biopsy for Point-of- Care Applications. Front Public Health 2017; 5:77
3. D. Chen, T. Xu, S. Wang, H. Chang, T. Yu, Y. Zhu, J. Chen, Liquid Biopsy Applications in the Clinic, Mol Diagn Ther 24 (2020) 125–132
4. M. Nikanjam, S. Kato, R. Kurzrock, Liquid biopsy: current technology and clinical applications, J Hematol Oncol 15 (2022) 131
5. M.J. Ijzerman, J. de Boer, A. Azad, K. Degeling, J. Geoghegan, C. Hewitt, F. Hollande, B. Lee, Y.H. To, R.W. Tothill, G. Wright, J. Tie, S.-J. Dawson, Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late, Diagnostics (2021),
6. T. Ashworth, Med. J. Aust., 1869, 14, 146.
7. I. J. Fidler, Eur. J. Cancer, 1973, 9, 223–227.
8. D. R. Coman, R. P. deLong and M. McCutcheon, Cancer Res., 1951, 11, 648.
9. I. Zeidman, Cancer Res., 1957, 17, 157–162.
10. Z. Deng, S. Wu, Y. Wang, D. Shi, Circulating tumour cell isolation for cancer diagnosis and prognosis, eBioMedicine 83 (2022),
11. P. Pinzani, V. D’Argenio, M. Del Re, C. Pellegrini, F. Cucchiara, F. Salvianti, S. Galbiati, Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumours, 59 (2021) 1181-1200.
12. B. Trujillo, A. Wu, D. Wetterskog, G. Attard, Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges, British Journal of Cancer 127 (2022) 1394–1402
13. H. Zhang, X. Lin, Y. Huang, M. Wang, C. Cen, S. Tang, M.R. Dique, L. Cai, M. A. Luis, J. Smollar, Y. Wan, F. Cai, Detection Methods and Clinical Applications of Circulating Tumour Cells in Breast Cancer, Frontiers in Oncology 11 2021
14. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–90.
15. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyurek LM, Lindahl P, Nilsson J. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med. 2015;7:308re308-308re308
16. E.S. Lianidou, A. Strati, A. Markou, Circulating tumour cells as promising novel biomarkers in solid cancers, Critical Reviews in Clinical Laboratory Sciences 51 (2014) 160–171
17. E. Heitzer, P. Ulz, J.B. Geigl, Circulating Tumour DNA as a Liquid Biopsy for Cancer, Clinical Chemistry 61 (2015) 112–123,
18. Q. Chen, Z.-H. Zhang, S. Wang, J.-H. Lang, Circulating cell-free DNA or circulating tumour DNA in the management of ovarian and endometrial cancer, OncoTargets and therapy 12 (2019) 11517
19. M. Ignatiadis, G.W. Sledge, S.S. Jeffrey, Liquid biopsy enters the clinic — implementation issues and future challenges, Nature Reviews Clinical Oncology 18 (2021) 297–312.
20. A.J. Bronkhorst, V. Ungerer, S. Holdenrieder, The emerging role of cell-free DNA as a molecular marker for cancer management, Biomolecular Detection and Quantification 17 (2019),
21. B. Bondhopadhyay, S. Sisodiya, F.A. Alzahrani, M.A. Bakhrebah, A. Chikara, V. Kasherwal, A. Khan, J. Rani, S.A. Dar, N. Akhter, P. Tanwar, U. Agrawal, S. Hussain, Exosomes: A Forthcoming Era of Breast Cancer Therapeutics, Cancers (2021)
22. C.A. Fitts, N. Ji, Y. Li, C. Tan, Exploiting exosomes in cancer liquid biopsies and drug delivery, Advanced healthcare materials 8 (2019), 1801268,
23. R. Kalluri, The biology and function of exosomes in cancer, The Journal of clinical investigation 126 (2016) 1208–1215, h
24. Oxnard GR, Thress KS, Alden RS, et al.: Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016, 34:3375-82.
25. Alix-Panabières C, Pantel K: Challenges in circulating tumour cell research . Nat Rev Cancer. 2014, 14:623-31.
26. Abbosh C, Birkbak NJ, Wilson GA, et al.: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017, 545:446-51.
27. Misawa K, Yamada S, Mima M, Nakagawa T, Kurokawa T, Imai A, et al.Long interspersed nuclear element 1 hypomethylation has novel prognostic value and potential utility in liquid biopsy for oral cavity cancer. Biomarker Research 2020; 8:53
28. Ginkel J H V, Huibers M M H, Noorlag R, Bree R, Van R J J, Willems S M. Liquid Biopsy: A Future Tool for Posttreatment Surveillance in Head and Neck Cancer? Pathobiology 2017; 84:115–120
29. Cui Y, Kim HS, Cho ES, Han D, Park J A, Park JY, Nam W, Kim HJ, Cha IH, Cha YH. Longitudinal detection of somatic mutations in saliva and plasma for the surveillance of oral squamous cell carcinomas. PLoS ONE 202; 16(9): e0256979
30. Khan RS, Khurshid Z, Yahya Ibrahim Asiri F. Advancing Point-of-Care (PoC) Testing Using Human Saliva as Liquid Biopsy. Diagnostics (Basel). 2017;7(3):39.
31. Michela B. Liquid Biopsy: A Family of Possible Diagnostic Tools. Diagnostics (Basel). 2021;11(8):1391.
32. J.J. Underwood, R.S. Quadri, S.P. Kalva, H. Shah, A.R. Sanjeevaiah, M.S. Beg, P. D. Sutphin, Liquid Biopsy for Cancer: Review and Implications for the Radiologist, Radiology 294 (2019) 5–17
Published
2024-07-06
How to Cite
HIMANSHU SINGH, Dr. BHUPESH BHAYYAJI BAGULKAR, DR. ARUNEE GARG, DR.URVASHI TOMAR, DR.ATUL BHAT, & DR.BHUVNESH AIREN. (2024). Liquid Biopsy : A Narrative Review. UNIVERSITY JOURNAL OF DENTAL SCIENCES, 10(2). https://doi.org/10.21276//ujds.2024.10.2.21
Section
Review Article
